NCT03710330View on ClinicalTrials.gov

Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section

PHASE4CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

March 30, 2020

Study Completion Date

August 1, 2020

Conditions
Cesarean Section Complications
Interventions
DRUG

normal saline

110 ml normal saline IV just before skin incision

DRUG

1gm tranexamic acid

1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision

DRUG

0.5 gm tranexamic acid

0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision

Trial Locations (1)

81528

Aswan University, Aswān

All Listed Sponsors
lead

Aswan University Hospital

OTHER

NCT03710330 - Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section | Biotech Hunter | Biotech Hunter